Compare PAYO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | ATAI |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 2025 |
| Metric | PAYO | ATAI |
|---|---|---|
| Price | $7.04 | $4.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $7.69 | ★ $15.88 |
| AVG Volume (30 Days) | ★ 12.4M | 5.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $10.28 | N/A |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $4.08 | $2.15 |
| 52 Week High | $7.67 | $6.73 |
| Indicator | PAYO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 79.17 | 62.27 |
| Support Level | $4.78 | $3.47 |
| Resistance Level | N/A | $4.68 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 95.70 | 78.60 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.